Sardi J E, di Paola G R, Giaroli A, Sananes C, Gómez Rueda N, Cachau A, Vighi S, Burlando S
Oncology Department of the First Chair of Gynecology, Buenos Aires University, Argentina.
Gynecol Oncol. 1988 Oct;31(2):256-61. doi: 10.1016/s0090-8258(88)80002-7.
Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri (VBP modified scheme) show that 85.7% of patients given this therapy were NED in Stage IIb versus 54% of a nonrandomized control group given conventional therapy. In Stage IIIb the averages are 66.6% vs. 31% in the control group. Analysis of the ecographic data has shown that if a critical prechemotherapy volume (120 cm3) is exceeded, the prognosis is unfavorable, especially in cases treated with radiotherapy as second-line treatment.
子宫颈癌新辅助化疗II期试验（VBP改良方案）结果显示，接受该治疗的IIb期患者中85.7%达到无疾病证据状态，而接受传统治疗的非随机对照组这一比例为54%。在IIIb期，相应平均值分别为66.6%和31%。超声数据分析表明，如果化疗前关键体积（120立方厘米）超标，预后不佳，尤其是接受放疗作为二线治疗的病例。
